SIGLEC6 and cancer: Similarly, Cyr et al.104 have developed an anti-SIGLEC6 monoclonal antibody achieving highly potent and specific elimination of SIGLEC6 positive leukemic and healthy B cells, thus indicating the potential for cancer immunotherapy.